Altamira Therapeutics Ltd
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses… Read more
Altamira Therapeutics Ltd (CYTO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: 2.114x
Based on the latest financial reports, Altamira Therapeutics Ltd (CYTO) has a cash flow conversion efficiency ratio of 2.114x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.86 Million) by net assets ($-1.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Altamira Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2012–2023)
This chart illustrates how Altamira Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Altamira Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Altamira Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
COLRUYT
BE:EFC1
|
N/A |
|
PILGRIMS PRIDE
BE:6PP
|
0.154x |
|
Klimat X Developments Inc.
V:KLX
|
0.123x |
|
AVISTA
BE:AV6
|
0.050x |
|
MUTUIONLINE
BE:MNL
|
N/A |
|
Ginegar
TA:GNGR
|
0.037x |
|
Gruppo Mutuionline SpA
STU:MNL
|
N/A |
|
NATURENERGIE
SW:NEAG
|
0.064x |
Annual Cash Flow Conversion Efficiency for Altamira Therapeutics Ltd (2012–2023)
The table below shows the annual cash flow conversion efficiency of Altamira Therapeutics Ltd from 2012 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $6.46 Million | $-11.51 Million | -1.782x | -270.66% |
| 2022-12-31 | $-8.31 Million | $-8.68 Million | 1.044x | +197.04% |
| 2021-12-31 | $12.70 Million | $-13.67 Million | -1.076x | -272.62% |
| 2020-12-31 | $16.77 Million | $-4.84 Million | -0.289x | +79.23% |
| 2019-12-31 | $6.04 Million | $-8.39 Million | -1.391x | +61.65% |
| 2018-12-31 | $3.65 Million | $-13.23 Million | -3.626x | -132.29% |
| 2017-12-31 | $-2.16 Million | $-24.28 Million | 11.227x | +639.11% |
| 2016-12-31 | $14.14 Million | $-29.45 Million | -2.083x | -224.36% |
| 2015-12-31 | $44.74 Million | $-28.73 Million | -0.642x | -77.11% |
| 2014-12-31 | $53.28 Million | $-19.32 Million | -0.363x | +76.68% |
| 2013-12-31 | $9.03 Million | $-14.04 Million | -1.555x | -108.43% |
| 2012-12-31 | $-244.03K | $-4.50 Million | 18.434x | -- |